News Jushi Holdings Inc. Amends and Refiles Q1 2022 Financial Statements Staff June 25, 2022 Iframe sync Post navigation Previous: Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext: Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ More Stories Cancer Diagnostics DNA Medicare News Patient Care Pharmaceutical Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Staff December 6, 2025 Cancer Clinical Trial News Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition Staff December 6, 2025 Cancer Clinical Trial News Pharmaceutical Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company’s RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma Staff December 6, 2025
